LEGN

Business Context and Reporting Period

Company: Legend Biotech Corporation
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2024
Report Date: August 9, 2024
Business Overview: Legend Biotech is a global biopharmaceutical company focused on cell therapies for oncology. Its lead product, CARVYKTI (cilta-cel), is a CAR-T therapy for multiple myeloma developed in collaboration with Janssen Biotech. The company also holds a global license agreement with Novartis for DLL3-targeting CAR-T therapies.

Key Financial Metrics

Note: Liquidity includes cash and cash equivalents ($201.3M), time deposits ($1.05B), and financial assets at fair value ($42.2M).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 156% to $280.5 million, driven by a $87.9 million increase in license revenue and a $77.3 million increase in collaboration revenue.
• License Revenue Drivers: Included $75.1 million in milestone payments from the Janssen Agreement and $27.9 million from the Novartis License Agreement (effective Dec 2023).
• Collaboration Revenue: Rose to $171.7 million due to increased net trade sales of CARVYKTI (approx. $186 million in net trade sales reported).
• Profitability Improvement: Net loss narrowed significantly from $311.2 million to $78.0 million, aided by a $60.7 million foreign currency exchange gain and higher interest income ($30.9 million).
• Expense Increases: R&D expenses rose 18% to $213.6 million; Selling and distribution expenses rose 38% to $54.3 million due to commercial expansion.
• Cash Position: Cash and cash equivalents decreased by approximately $1.08 billion, primarily due to the purchase of time deposits ($2.2 billion) and financial assets, partially offset by withdrawals.

Guidance, Outlook, and Risks

• Outlook: Management expects to achieve operating profit in 2026. Current liquidity of approximately $1.3 billion is projected to fund operations and capital expenditures into 2026.
• Recent Developments: FDA approved CARVYKTI for earlier lines of treatment (second line) in April 2024. MHRA and Health Canada also approved earlier line indications. Positive overall survival results were reported in the CARTITUDE-4 study.
• Risks and Contingencies:
  • Liquidity: The company has incurred significant losses since inception and expects to continue doing so until commercialization scales.
  • Regulatory: Risks include unexpected clinical trial results, regulatory delays, or pricing pressures.
  • Macroeconomic: Inflation and global conflicts could impact costs and supply chains, though no material impact was reported to date.
  • Debt: Outstanding advances from Janssen ($250M principal + interest) accrue interest based on SOFR and are recoupable from future collaboration profits.

Key Facts for Investor Verification

• Revenue Recognition Timing: Verify the sustainability of the $103 million license revenue, which includes significant milestone payments from Janssen and Novartis that may not recur at the same frequency.
• Cash Deployment: Confirm the strategy behind the massive shift of liquid cash into time deposits ($1.05 billion) and the impact on immediate liquidity flexibility.
• Operating Profit Timeline: Assess the feasibility of the 2026 operating profit target given the continued increase in R&D and commercialization expenses.
• Collaboration Dependency: Review the terms of the Janssen Agreement regarding the recoupment of the $291.6 million interest-bearing advanced funding from future profits.
• Foreign Exchange Impact: Note that the significant reduction in net loss was partially driven by a $60.7 million unrealized foreign currency exchange gain, which is a non-operating item.